Database

Startups

Main Industry
Health Care
Main Product/Service
Edge AI Solutions
AI Inference Device
DeviceEdge Jetson Series
DeviceEdge AI on ARM Series
AI Inference / Training System
MegaEdge PCIe Series
MegaEdge M.2 Series
MegaEdge MXM Series
AI Inference / Training Server
AI Accelerator & GPU
CoreEdge PCIe Card
Intel Arc Graphics
NVIDIA RTX Graphics
CoreEdge MXM Module
MXM Module
Expansion Kit
Software & Service
Cloud Management Platform
Founded Year
2022
Unified Business No.
90268289
Status
Active
Number of Employees
0
Total Paid-in Capital
55,099,670 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
Having established its expertise in GPU accelerators, edge computing, and system integration, Aetina empowers businesses to innovate with confidence. From rapid exploration, development and deployment of domain-specific, industrial-grade edge AI solutions, Aetina is the trusted partner you need for every step of the way. Our one-stop service streamlines the implementation of edge AI applications for businesses. It propels our clients to the edge of their imagination, fueling digital transformation beyond conventional boundaries.



More ↓

Similar Companies

TRUST BIO-SONICS INC.

1. Ultrasound Imaging Agents
2. Ultrasound-Mediated Targeted Delivery

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization